NCT02145403View on ClinicalTrials.gov

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

November 26, 2018

Study Completion Date

October 16, 2020

Conditions
Hematologic MalignanciesRelapseGraft-Versus-Host Disease
Interventions
DRUG

Carfilzomib

"Carfilzomib will be administered starting at dose level 1 (20 mg/m2 IV) on day +1, +2, +6 and +7.~Dose escalation will be performed on the day +6 and day +7 doses only in each dose level. Day +1 and day+2 doses will be fixed at 20 mg/m2 IV in all dose levels."

DRUG

Tacrolimus

Tacrolimus will be administered at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.

Trial Locations (1)

48109

University of Michigan Hospital, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT02145403 - Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies | Biotech Hunter | Biotech Hunter